Monte Rosa Therapeutics, Inc. Foreign Currency Transaction Gain (Loss), before Tax
Monte Rosa Therapeutics, Inc. (GLUE) reported Foreign Currency Transaction Gain (Loss), before Tax of $25.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $25.00K, a 98.20% decline year-over-year.
- Monte Rosa Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$8.00K, a 104.62% decline year-over-year.
- Monte Rosa Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$50.00K, a 2600.00% decline year-over-year.
- Monte Rosa Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$29.00K.
- Monte Rosa Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2025 was $1.48M, a 256.73% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2024 was $416.00K.
- Monte Rosa Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2023 was -$930.00K, a 9400.00% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2022 was $10.00K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.00K 10-Q · filed 2026-08-06 | $17.00K 10-Q · filed 2026-08-06 | -$33.00K derived: sum of 3 quarters · filed 2026-08-06 | -$62.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$8.00K 10-Q · filed 2026-05-07 | -$58.00K derived: sum of 2 quarters · filed 2026-05-07 | -$87.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$79.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.31M derived: sum of 3 quarters · filed 2026-08-06 | $1.48M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$29.00K 10-Q · filed 2025-11-06 | $1.36M derived: sum of 2 quarters · filed 2026-08-06 | $1.53M 10-Q · filed 2025-11-06 | $1.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.39M 10-Q · filed 2026-08-06 | $1.56M 10-Q · filed 2026-08-06 | $1.56M derived: sum of 3 quarters · filed 2026-08-06 | $1.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $173.00K 10-Q · filed 2026-05-07 | $175.00K derived: sum of 2 quarters · filed 2026-05-07 | $22.00K derived: sum of 3 quarters · filed 2026-05-07 | -$31.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$151.00K derived: sum of 2 quarters · filed 2026-03-17 | -$204.00K derived: sum of 3 quarters · filed 2026-03-17 | $416.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | -$153.00K 10-Q · filed 2025-11-06 | -$206.00K derived: sum of 2 quarters · filed 2025-11-06 | $414.00K 10-Q · filed 2025-11-06 | -$365.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$53.00K 10-Q · filed 2025-08-07 | $567.00K 10-Q · filed 2025-08-07 | -$212.00K derived: sum of 3 quarters · filed 2025-08-07 | -$185.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $620.00K 10-Q · filed 2025-05-08 | -$159.00K derived: sum of 2 quarters · filed 2025-05-08 | -$132.00K derived: sum of 3 quarters · filed 2025-05-08 | -$225.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$752.00K derived: sum of 2 quarters · filed 2025-03-20 | -$845.00K derived: sum of 3 quarters · filed 2025-03-20 | -$930.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $27.00K 10-Q · filed 2024-11-07 | -$66.00K derived: sum of 2 quarters · filed 2024-11-07 | -$151.00K 10-Q · filed 2024-11-07 | -$434.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$93.00K 10-Q · filed 2024-08-08 | -$178.00K 10-Q · filed 2024-08-08 | -$461.00K derived: sum of 3 quarters · filed 2024-08-08 | -$398.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$85.00K 10-Q · filed 2024-05-09 | -$368.00K derived: sum of 2 quarters · filed 2024-05-09 | -$305.00K derived: sum of 3 quarters · filed 2024-05-09 | -$171.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$283.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$220.00K derived: sum of 2 quarters · filed 2024-03-14 | -$86.00K derived: sum of 3 quarters · filed 2024-03-14 | $10.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $63.00K 10-Q · filed 2023-11-09 | $197.00K derived: sum of 2 quarters · filed 2023-11-09 | $293.00K 10-Q · filed 2023-11-09 | $227.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $134.00K 10-Q · filed 2023-08-10 | $230.00K 10-Q · filed 2023-08-10 | $164.00K derived: sum of 3 quarters · filed 2023-08-10 | $182.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $96.00K 10-Q · filed 2023-05-11 | $30.00K derived: sum of 2 quarters · filed 2023-05-11 | $48.00K derived: sum of 3 quarters · filed 2023-05-11 | -$248.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$48.00K derived: sum of 2 quarters · filed 2023-03-16 | -$344.00K derived: sum of 3 quarters · filed 2023-03-16 | -$162.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $18.00K 10-Q · filed 2022-11-10 | -$278.00K derived: sum of 2 quarters · filed 2022-11-10 | -$96.00K 10-Q · filed 2022-11-10 | -$145.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$296.00K 10-Q · filed 2022-08-11 | -$114.00K 10-Q · filed 2022-08-11 | -$163.00K derived: sum of 3 quarters · filed 2022-08-11 | -$337.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $182.00K 10-Q · filed 2022-05-11 | $133.00K derived: sum of 2 quarters · filed 2022-05-11 | -$41.00K derived: sum of 3 quarters · filed 2022-05-11 | -$10.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$223.00K derived: sum of 2 quarters · filed 2022-03-29 | -$192.00K derived: sum of 3 quarters · filed 2022-03-29 | -$198.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | -$174.00K 10-Q · filed 2021-11-10 | -$143.00K derived: sum of 2 quarters · filed 2021-11-10 | -$149.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $31.00K 10-Q · filed 2021-08-12 | $25.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |